|
MechanismKRAS G12V inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismKRAS G12D inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Prosite (Nanjing) Biotechnology Co., Ltd.
0 Patents (Medical) associated with Prosite (Nanjing) Biotechnology Co., Ltd.
100 Deals associated with Prosite (Nanjing) Biotechnology Co., Ltd.
100 Translational Medicine associated with Prosite (Nanjing) Biotechnology Co., Ltd.